Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: A case report

Alessandra Bearz, Sandra Santarossa, Antonio Manfrè, Giorgio Beltrame, Martina Urbani, Ivana Sartor, Valentina Da Ros, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

Background: Adenocarcinoma of the lung with EML4-ALK translocation is a rare subtype of Non Small-Cell Lung Cancer (NSCLC) that has recently shown to benefit from treatment with crizotinib. Despite the concerns about the efficacy of crizotinib over cerebral metastases, some reports have described its activity, although always after local treatment with radiotherapy. Recently it has been reported activity of crizotinib over choroidal metastases, again after radiotherapy. Case presentation. Herein we report a case of activity of crizotinib over choroidal metastases not previously treated with radiotherapy. Conclusion: We suggest crizotinib may be active over choroidal metastases in a patient harboring ALK translocation with no need of radiotherapy.

Original languageEnglish
Article number589
JournalBMC Research Notes
Volume7
Issue number1
DOIs
Publication statusPublished - Sep 2 2014

    Fingerprint

Keywords

  • ALK-translocation
  • Choroidal metastasis
  • NSCLC

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this